Manami Takahashi-Watanabe - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Filters

Manami Takahashi-Watanabe

Showing results (1-10 of 10) with videos related to

Pageof 1

Sort By:

The Journal of Dermatology|March 17, 2026

Successful Control of Langer hans Cell Sarcoma in a Super-Aged Patient Using Intensity-Modulated RadiotherapyHiromu Okuguchi, Taku Fujimura, Manami Takahashi-Watanabe, et al.

The Journal of Dermatology|October 28, 2025

Three Cases of Advanced Melanoma With Severe irAE Colitis With Rapid Tumor Progression Following Infliximab AdministrationEmi Yamazaki, Taku Fujimura, Yumi Kambayashi, et al.

The Journal of Dermatology|March 25, 2025

Two cases of advanced melanoma with BRAF L597 mutation: Options for systemic treatmentRyo Amagai, Taku Fujimura, Yumi Kambayashi, et al.

The Journal of Dermatology|April 17, 2024

Radiation-induced cutaneous squamous cell carcinoma showing a significant response to pembrolizumab: A case reportManami Takahashi-Watanabe, Taku Fujimura, Ryo Amagai, et al.

European Journal of Dermatology : EJD|August 28, 2024

Steroid-resistant Vogt-Koyanagi-Harada-like uveitis due to BRAF/MEK inhibitor, successfully treated with adalimumabManami Takahashi-Watanabe, Taku Fujimura, Ryo Amagai, et al.

Journal of Clinical Medicine|February 26, 2025

An Evaluation of Prognostic Factors in Cutaneous Squamous Cell Carcinoma: A Single-Center Study of 237 Japanese CasesEmi Yamazaki, Taku Fujimura, Manami Takahashi-Watanabe, et al.

The British Journal of Dermatology|August 31, 2024

Decreased interleukin 4 serum levels correlate with plasminogen activator inhibitor-1 inhibitor TM5614 efficacy in patients with malignant melanoma refractory to anti-programmed cell death protein-1 antibodies: post hoc study of the TM5614-MM trialEmi Yamazaki, Taku Fujimura, Manami Takahashi-Watanabe, et al.

Case Reports in Oncology|July 10, 2025

A Super-Aged Patient with Primary Cutaneous Gamma-Delta T-Cell Lymphoma Treated with Palliative Radiotherapy: A Short-Term Follow-Up CaseMoyuka Wada-Irimada, Taku Fujimura, Manami Takahashi-Watanabe, et al.

JAAD International|March 9, 2026

Clinical utility of comprehensive genomic profiling in 175 Japanese patients with advanced skin malignancies refractory to standard therapiesYumi Kambayashi, Taku Fujimura, Hiroshi Kato, et al.

Experimental Dermatology|January 8, 2026

Phase III Study Investigating the Safety and Efficacy of TM5614 in Combination With Nivolumab for the Treatment of Unresectable Malignant Melanoma: ProtocolTaku Fujimura, Koji Yoshino, Hiroshi Kato, et al.

Pageof 1

Search research articles

Showing results (1-10 of 10) with videos related to

Sort By:

Pageof 1

The Journal of Dermatology|March 17, 2026

Successful Control of Langer hans Cell Sarcoma in a Super-Aged Patient Using Intensity-Modulated RadiotherapyHiromu Okuguchi, Taku Fujimura, Manami Takahashi-Watanabe, et al.

The Journal of Dermatology|October 28, 2025

Three Cases of Advanced Melanoma With Severe irAE Colitis With Rapid Tumor Progression Following Infliximab AdministrationEmi Yamazaki, Taku Fujimura, Yumi Kambayashi, et al.

The Journal of Dermatology|March 25, 2025

Two cases of advanced melanoma with BRAF L597 mutation: Options for systemic treatmentRyo Amagai, Taku Fujimura, Yumi Kambayashi, et al.

The Journal of Dermatology|April 17, 2024

Radiation-induced cutaneous squamous cell carcinoma showing a significant response to pembrolizumab: A case reportManami Takahashi-Watanabe, Taku Fujimura, Ryo Amagai, et al.

European Journal of Dermatology : EJD|August 28, 2024

Steroid-resistant Vogt-Koyanagi-Harada-like uveitis due to BRAF/MEK inhibitor, successfully treated with adalimumabManami Takahashi-Watanabe, Taku Fujimura, Ryo Amagai, et al.

Journal of Clinical Medicine|February 26, 2025

An Evaluation of Prognostic Factors in Cutaneous Squamous Cell Carcinoma: A Single-Center Study of 237 Japanese CasesEmi Yamazaki, Taku Fujimura, Manami Takahashi-Watanabe, et al.

The British Journal of Dermatology|August 31, 2024

Decreased interleukin 4 serum levels correlate with plasminogen activator inhibitor-1 inhibitor TM5614 efficacy in patients with malignant melanoma refractory to anti-programmed cell death protein-1 antibodies: post hoc study of the TM5614-MM trialEmi Yamazaki, Taku Fujimura, Manami Takahashi-Watanabe, et al.

Case Reports in Oncology|July 10, 2025

A Super-Aged Patient with Primary Cutaneous Gamma-Delta T-Cell Lymphoma Treated with Palliative Radiotherapy: A Short-Term Follow-Up CaseMoyuka Wada-Irimada, Taku Fujimura, Manami Takahashi-Watanabe, et al.

JAAD International|March 9, 2026

Clinical utility of comprehensive genomic profiling in 175 Japanese patients with advanced skin malignancies refractory to standard therapiesYumi Kambayashi, Taku Fujimura, Hiroshi Kato, et al.

Experimental Dermatology|January 8, 2026

Phase III Study Investigating the Safety and Efficacy of TM5614 in Combination With Nivolumab for the Treatment of Unresectable Malignant Melanoma: ProtocolTaku Fujimura, Koji Yoshino, Hiroshi Kato, et al.

Pageof 1